Table 1. CF Center NACFC Presentations (2020-2023)

Presentation / Award	Category
Virtual: October 7-23, 2020	
Peabody Lever, J.E; Kim, H; Edwards, L; Bodduluri, S; McMillian, E; Rosen, B.H; Engelhardt, J; Phillips, S.E; Rowe, S. Ivacaftor improves mucociliary clearance in vivo in diseased G551D transgenic ferrets. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 1), 2020	Poster
Harris, E.S; Fernandez-Petty, C.M; Abou Daya, F; Johns, J.D; Margaroli, C; Baker, S; Weismann, W.P; Birket, S; Rowe, S. Effects of SNSP113 (PAAG) on mucus obstruction in the b-enac murine model of CF lung disease. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 3), 2020	Poster
Yu, L; Khimchenko, A; Leung, H.M; Birket, S; Rowe, S; Tearney, G.J. Probing of CF mucus microrheology with magnetomotive micro-optical coherence tomography. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 36), 2020	Poster
Margaroli, C; Li, J; Viera, L; Gaggar, A; Xu, X. Modulation of LTA4H aminopeptidase activity by neutrophil elastase in cystic fibrosis airway disease. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 49), 2020	Poster
Gridley, J; Fan, Y; Li, C; Wang, X.R. Impact of CFTR correctors on the channel activity of rescued F508 CFTR, an important factor in efficacious functional rescue. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 82), 2020	Poster
Cho, D; Zhang, S; Skinner, D; Lazrak, A; Bebok, Z; Thompson, H; Grayson, J; Rowe, S; Matalon, S; Woodworth, B.A. LPS decreases CFTR open probability and markers of mucociliary transport through generation of reactive oxygen species. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 95), 2020	Poster
Kazmerski, T.M; Stransky, O.M; Taylor-Cousar, J.L; Sawicki, G.S; Ladores, S.L; Godfrey, E.M; Aitken, M.L; Sufian, S; Jain, M; Barto, T.L; Billings, J; Hadjiliadis, D; Jain, R. Sexual and reproductive health behaviors and experiences of adult women with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 138), 2020	Poster
Oates, G.R; Baker, E; Rutland, S.B; Harris, W.T; Rowe, S. Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 139), 2020	Poster
Bailey, J; Juarez, L.D; Rutland, S.B; Oates, G.R. Prevalence and correlates of overweight and obesity in a national cohort of children and adolescents with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 144), 2020	Poster
Kazmerski, T.M; Stransky, O.M; Taylor-Cousar, J.L; Sawicki, G.S; Ladores, S.L; Godfrey, E.M; Aitken, M.L; Sufian, S; Jain, M; Barto, T.L; Billings, J; Hadjiliadis, D; Jain, R. Sexual and reproductive health care utilization and preferences of adult women with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 146), 2020	Poster
Oates, G.R; Baker, E; Rutland, S.B; Harris, W.T; Rowe, S. Cessation of smoke exposure improves pediatric CF outcomes: longitudinal analysis of patient registry data. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 147), 2020	Poster
Rutland, S.B; Juarez, L.D; Schechter, M.S; Oates, G.R. The association of area deprivation and overall child health with pediatric CF respiratory outcomes in the united states. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 150), 2020	Poster
Oliver, K.E; Mao, Y; Laflin, S; Linscott, K; Gaines, E; Ali, H; Hong, J.S; Rab, A; Sorscher, E.J; Hartman, J.L. Utilizing yeast phenomics to discover gene interaction networks that influence biogenesis of CFTR nonsense alleles. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 204), 2020	Poster
Hoffman, L; Pope, C; Hayden, H; Rowe, S; Salipante, S; Nichols, D.P. Changes in fecal fat and microbiota with 1 month of elexacator/tezacaftor/ivacaftor: initial findings from the promise study. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 218), 2020	Poster

Presentation / Award	Category
Lai, H.J; Lu, Q; Song, J; Farrell, P.M; Brown, D.M; Worthey, E; FIRST Study Group. Genetic factors help explain the response of children with CF to vitamin d supplements during their first two years. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 224), 2020	Poster
McDaniel, M.S; Schoeb, T; Swords, W.E. Stenotrophomonas maltophilia synergizes with pseudomonas aeruginosa in polymicrobial airway infections. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 294), 2020	Poster
Baty, J; Huffines, J; Scoffield, J. Nitric oxide reductase is critical for p. aeruginosa tolerance to streptococcus parasanguinis-mediated nitrosative stress. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 300), 2020	Poster
Lindgren, N.R; Hunt, B.C; McDaniel, M.S; Swords, W.E. Impact of successional changes in the microbial populations of the CF lung. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 312), 2020	Poster
Cho, D; Skinner, D; Zhang, S; Lim, D; Thompson, H; Koch, C; Rowe, S; Tearney, G.J; Woodworth, B.A. Red ginseng aqueous extract improves markers of mucociliary clearance in the cystic fibrosis rat. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 376), 2020	Poster
Du, M; Liu, K; Dai, Y; Fu, L.K; Keeling, K.M. Bedwell, D. Development of second generation nanoluc-based reporters containing CFTR-specific PTCs for identifying readthrough compounds. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 380), 2020	Poster
Kabir, F.Z; Anderson, J.D; Liu, Z; Liu, Z; Sasaki, S; Huang, L; Guo, S; Rowe, S; Zhao, R; Guimbellot, J.S; Harris, W.T. MIR-145 inhibition in pluripotent stem cells and conditionally reprogrammed nasospheroids improves f508del correction: two patient-derived model systems to test personalized response to CFTR-directed oligotherapeutics. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 388), 2020	Poster
Barillà, C; Suzuki, S; Rab, A; Goller, K; Hong, J.S; Driggers, W.C; Flores, J; Feldman, R.J; Solomon, G.M; Stecenko, A; Sorscher, E.J; Davis, B.R. Application of IPSC-derived airway epithelium for evaluating the response of rare or unknown CFTR mutations to modulators. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 395), 2020	Poster
Liu, Z; Anderson, J.D; Liu, Z; Rowe, S; Bedwell, D; Guimbellot, J.S; Zhao, R. Using patient cell-derived induced pluripotent stem cells as an in vitro model to assess CF drug efficacy. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 402), 2020	Poster
Chen, J; Li, Y; Peng, N; Tang, L; Falk Libby, E; Rowe, S; Mutyam, V. Wlexacaftor/tezacaftor/ivacaftor enhances the function of CFTR following readthrough therapy of premature termination codons in vitro. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 412), 2020	Poster
Donaldson, S.H; Corcoran, T.E; Mogayzel, P.J; Laube, B; Pilewski, J.M; Boitet, E.R; Harris, E.S; Liu, B; Ceppe, A; Edwards, L; Zeman, K; Wu, J; Bennett, W.D; Rowe, S. Effect of elexacaftor/tezacaftor/ivacaftor on mucociliary clearance and mucus properties: the PROMISE mucus/MCC sub-study. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 413), 2020	Poster
Abou Daya, F; Boitet, E.R; Rowe, S. Amphotericin b improves airway surface hydration and mucus transport in primary f508del-homozygous human bronchial epithelial cells. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 425), 2020	Poster
Anderson, J.D; Liu, Z; Odom, L.V; Guimbellot, J.S. HNE organoids closely recapitulate short circuit current and clinical responses from patients. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 426), 2020	Poster
Linnemann, R.W; Streby, A; Rab, A; Solomon, G.M; Hunter, E; Hailemichael, T; Driggers, W.C; Slaten, K; Hathorne, H; Hong, J.S; Suzuki, S; Barillà, C; Davis, B.R; Stecenko, A; Sorscher, E.J. IPS-derived airway cell response to CFTR modulation: study of triple combination therapy in CF patients without an approved modulator. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 431), 2020	Poster
Nichols, D.P; Paynter, A; Kirby, S; VanDalfsen, J; Khan, Z; Heltshe, S.L; Donaldson, S.H; Frederick, C.A; Freedman, S; Gelfond, D; Hoffman, L; Kelly, A; Narkewicz, M.R; Sagel, S; Schwarzenberg, S; Singh, P; Solomon, G.M; Stalvey, M.S; Clancy, J.P; Rowe, S. Clinical effectiveness of	Poster

Presentation / Award	Category
elexacaftor/tezacaftor/ivacaftor: the longitudinal PROMISE study. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 441), 2020	
Solomon, G.M; Leung, H.M; Boitet, E.R; Amilcar, B; Wade, J; Birket, S; Joseph, R; Edwards, L; Tearney, G.J; Rowe, S. Mechanistic investigation of the mucociliary response to triple combination modulator therapy in F508del CF. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 451), 2020	Poster
Krick, S; Lowman, J.D; Bailey, J; Wade, J; Hathorne, H; Edwards, L; Rowe, S. Effect of the triple combination modulator therapy on exercise tolerance in CF patients. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 464), 2020	Poster
Nichols, D.P; Morgan, S.J; Singh, S.B; Rowe, S; Hoffman, L; Singh, P. Elexacaftor/tezacaftor/ivacaftor markedly reduces sputum pathogen density in people with CF; a promise study. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 465), 2020	Poster
Bray, L.A; Campbell, C; Brown, J.L; Ladores, S.L. Exploration of paths to motherhood in cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 486), 2020	Poster
Ladores, S.L; Campbell, C; Sufian, S; Bray, L.A. Fertility and fertility preservation in women with cystic fibrosis pre-lung transplantation. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 487), 2020	Poster
	Poster
Brown, J.L; Bray, L.A; Kazmerski, T.M; Ladores, S.L. Exploring the interplay between self efficacy and sexual and reproductive health in women with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 489), 2020	Poster
Bray, L.A; Baswell, K; Brown, J.L; Ladores, S.L. Body image and weight in adults with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 494), 2020	Poster
Liang, F; Van Drie, J.H; Shang, H; Jordan, N; Smith, J; Wang, L; Cantu, S; Du, M; Bedwell, D; Bihler, H; Mense, M. Targeting translation termination for pharmacological readthrough of PTC variants of CFTR. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 507), 2020	Poster
Kabir, F.L; Sharma, J; Sasaki, S; Huang, L; Guo, S; Ambalavanan, N; Rowe, S; Harris, W.T. Antisense oligotherapeutic target site blockade against mir-145: a mutation agnostic approach to improve CFTR correction. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 510), 2020	Poster
Thrasher, K; Xue, X; Benson, D; Mobley, J; Renfrow, M.B; Keeling, K.M; Bedwell, D. Evaluating the CFTR protein variants created upon readthrough. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 518), 2020	Poster
Frederick, C.A; Dunn, K.M; Green, A; Hall, S; Lindwall, J; Maggs, J; Moffett, K; Phan, H; Prickett, M; Saavedra, M.T; Oates, G.R. Perspectives of the CF community on research ideas related to self-management and adherence. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 596), 2020	Poster
Corcoran, J.L; Li, P; Campbell, C; Bray, L.A; Ladores, S.L. Measuring knowledge of fertility preservation in women with cystic fibrosis: instrument development and psychometric analysis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 601), 2020	Poster
Bermingham, B; Rueschhoff, A; Ratti, G.A; NeSmith, A; Flume, P; Solomon, G.M; Cohen, L; Garcia, B. A multi-center retrospective analysis of the clinical efficacy of elexacaftortezacaftor-ivacaftor in patients with advanced lung disease. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 645), 2020	Poster
Thomas, L.K; Albon, D; Ong, T; Gammon, C; Gamel, B; Orcutt, Z; Powers, M.R. Rapid innovation and learning structure in the CF learning network: the telehealth ilab. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 677), 2020	Poster
Self, S.; Rutland, S.B.; Oates, G.R.; Gutierrez, H. Optimizing newborn screening for cystic fibrosis in Alabama: a QI project. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 690), 2020	Poster
Self, S; Mims, C.R; Gutierrez, H; Guimbellot, J.S. Evidence-based guideline implementation for CFTR-related metabolic syndrome. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 721), 2020	Poster

Presentation / Award	Category
Rutland, S.B; Bergquist, R; Hager, A; Geurs, R; Mims, C.R; Gutierrez, H; Oates, G.R. Adaptation of a mobile health patient support platform to the needs of cystic fibrosis patients, caregivers, and clinicians in the United States. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 736), 2020	Poster
Mims, C.R; Anderson, V; Gamble, S; Dunn, J; Mabrey, E; Gutierrez, H. Implementation of multidisciplinary telehealth CF clinics. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 753), 2020	Poster
Dickinson, K.M; Eckmann, T; Quittner, A.L; Butcher, J.L; Oates, G.R; Prickett, M; Schechter, M.S; Riekert, K.A. Socioeconomic status effects on adherence barriers to chronic therapies in CF. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 794), 2020	Poster
NeSmith, A; Bailey, J; Chaudary, N; Sawicki, G.S; Uluer, A.Z; Solomon, G.M. Multicenter assessment of telehealth experience of care in adult people with cystic fibrosis. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 797), 2020	Poster
Davis, J; Perkins, R; Barnico, K; Froh, D; Bailey, J; Gordon, R; NeSmith, A; Siracusa, C; Sawicki, G.S. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 799), 2020	Poster
Perkins, R.; Davis, J; Bailey, J; NeSmith, A; Solomon, G.M; Sawicki, G.S; Siracusa, C. Telehealth implementation in cystic fibrosis care during covid-19: the clinician experience. Pediatric Pulmonology Supp Volume 55, Issue S2 (Abstract 810), 2020	Poster
J. Peabody Lever. Top 3 Abstract in Airway Physiology. “Ivacaftor improves mucociliary clearance in vivo in disease G551D transgenic ferrets.”	Workshop
L. Bray. Top 3 Abstract in Nursing. “Exploration of paths to motherhood in cystic fibrosis.”	Workshop
J. Brown. Top 3 Abstract in Nursing. “Exploring the interplay between self-efficacy and sexual and reproductive health in women with cystic fibrosis.”	Workshop
S. Ladores. Top 3 Abstract in Nursing. “Fertility and fertility preservation in women with cystic fibrosis pre-lung transplantation.”	Workshop
S. Birket. “The CF Rat as a Model for Advancing Novel Therapeutics.”	Symposium
J. Scoffield. “Commensal streptococci. A potential defense strategy against Pseudomonas aeruginosa persistence.’	Symposium
J. Lowman. “The importance of exercise in achieving optimal health for people with CF.”	Symposium
M. Stalvey. “Effects of highly effective CFTR modulators on extrapulmonary manifestations of CF.”	Symposium
J. Guimbellot. “Pharmacologic considerations in drug response in CF.”	Symposium
GM. Solomon. “Challenges of precision medicine in CF.”	Symposium
GM. Solomon. “Clinical year in review.”	Symposium
Virtual: November 2-5, 2021	
J. Bailey, J. Wade, D. Redden, S. Rowe, G. Solomon. Nutritional and metabolic effects of elexacaftor/tezacaftor/ivacaftor in adults and adolescents with cystic fibrosis. Pediatric Pulmonology Supp Volume 20, Supplement 2 (Abstract 216), 2021	Poster
E. Harris, E. Helton, M. Mazur, S. Krick, S. Rowe, J. Barnes. Altered mucin sialylation results in delayed mucociliary transport in CF. Pediatric Pulmonology Supp Volume 20, Supplement 2 (Abstract 352), 2021	Poster

Presentation / Award	Category
L. Yu, H. Leung, S. Birket, S. Rowe, G. Tearney. Advances of magnetomotive micro-optical coherence tomography for mucus microrheology. Pediatric Pulmonology Supp Volume 20, Supplement 2 (Abstract 384), 2021	Poster
S. Morgan, A. Vo, W. Ni, M. Radey, K. McGeer, S. Rowe, P. Jorth, S. Singh, D. Nichols, P. Singh. Effects of elexacaftor/tezacaftor/ivacaftor on the CF sputum microbiome: Preliminary analysis from the Promise study. Pediatric Pulmonology Supp Volume 20, Supplement 2 (Abstract 429), 2021	Poster
D. Cho, D. Skinner, S. Zhang, D. Lim, W. Swords, R. Hunter, S. Rowe, B. Woodworth. Adaptation of Pseudomonas aeruginosa isolates from cystic fibrosis patients to the anaerobic environment. Pulmonology Supp Volume 20, Supplement 2 (Abstract 445), 2021	Poster
D. Bedwell, J. Sharma, M. Du, E. Wong, V. Mutyam, Y. Li, J. Chen, J. Wangen, K. Thrasher, L. Fu, N. Peng, L. Tang, K. Liu, B. Mathew, B. Bostwick, C. Augelli-Szafran, H. Bihler, F. Liang, J. Mahiou, J. Saltz, A. Rab, J. Hong, E. Sorscher, E. Mendenhall, C. Coppola, K. Keeling, R. Green, M. Mense, M. Suto, S. Rowe. Identification of a compound that mediates readthrough of CFTR nonsense mutations by reducing eRF1 levels. Pulmonology Supp Volume 20, Supplement 2 (Abstract 531), 2021	Poster
V. Mutyam, N. Peng, Y. Li, J. Chen, S. Rowe. Restoration of CFTR-dependent current by readthrough therapy in 2-D organoid monolayers derived from patients with nonsense mutations. Pulmonology Supp Volume 20, Supplement 2 (Abstract 532), 2021	Poster
S. Rowe, D. Dorgan, J. Lascano, J. Zuckerman, K. McCoy M. Jain, M. Schechter, S. Lommatzsch, V. Indihar, N. Lechtzin, K. McBennett, J. Callison, C. Brown, T. Liou, K. MacDonald, S. Nasr, S. Bodie, E. Meltzer, A. Barbier. Safety and tolerability of single and repeat doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients. Pulmonology Supp Volume 20, Supplement 2 (Abstract 544), 2021	Poster
J. Chen, V. Mutyam, N. Peng, Y. Li, L. Tang, S. Rowe. New combination readthrough agents and CFTR corrector therapy to improve CFTR function of cystic fibrosis with nonsense mutation. Pulmonology Supp Volume 20, Supplement 2 (Abstract 552), 2021	Poster
E. Gaines, R. Mancinone, S. Laflin, W. Wang, S. Rowe, K. Oliver, Y. Mao, A. Rab, J. Hong, E. Sorscher, J. Hartman. YOR1 modeling of CFTR nonsense variants to discover effects of genetic factors and sequence context on efficacy of PTC suppression. Pulmonology Supp Volume 20, Supplement 2 (Abstract 581), 2021	Poster
F. Kabir, Z. Liu, J. Anderson, D. Crossman, S. Sasaki, L. Huang, S. Guo, J. Guimbellot, S. Rowe, W. Harris. Antisense oligonucleotide target site blockade of miR-145 binding selectively enhances CFTR correction in airway epithelial cells and nasal organoids. Pulmonology Supp Volume 20, Supplement 2 (Abstract 602), 2021	Poster
Z. Liu, C. Zhang, C. Li, Z. Liu, S. Rowe, D. Bedwell, J. Guimbellot, H. Li, R. Zhao. Generation and characterization of a patient-derived iPSC line carrying the CFTR G542X/G542X mutation. Pulmonology Supp Volume 20, Supplement 2 (Abstract 671), 2021	Poster
N. Lindgren, L. Novak, M. McDaniel, W. Swords. Impact of sequentially introduced non-typeable Haemophilus influenzae and Pseudomonas aeruginosa on CF lungs. Pulmonology Supp Volume 20, Supplement 2 (Abstract 424), 2021	Poster
C. Billiot, M. McDaniel, W. Swords. Achromobacter xylosoxidans as a cystic fibrosis–related opportunist. Pulmonology Supp Volume 20, Supplement 2 (Abstract 457), 2021	Poster
K. Thrasher, X. Xue, D. Benson, M. Renfrow, K. Keeling, D. Bedwell. Evaluating protein variants created by readthrough of CFTR nonsense mutations. Pulmonology Supp Volume 20, Supplement 2 (Abstract 606), 2021	Poster
G. Solomon, S. Bichl, S. Gomez, C. Gammon, K. Petren, R. Amin, C. Ren. Improved recognition and treatment of FEV1-indicated exacerbation signal (FIES) through an iLab approach. Pulmonology Supp Volume 20, Supplement 2 (Abstract 111), 2021	Poster
R. Linnemann, G. Solomon, A. Streby, A. Rab, W. Driggers, K. Slaten, H. Hathorne, J. Hong, S. Suzuki, B. Wang, C. Barillà, A. Stecenko, B. Davis, E. Sorscher. Clinical and iPSC-derived airway	Poster

Presentation / Award	Category
epithelial responses to elexacaftor/tezacaftor/ivacaftor in CF patients without an approved modulator. Pulmonology Supp Volume 20, Supplement 2 (Abstract 572), 2021	
J. Brewington, J. Hong, C. Manfredi, A. Rab, D. Joshi, R. Linnemann, A. Streby, A. Stecenko, A. Ostmann, R. O'Shaughnessy, H. Morgan, J. Meeker, S. Suzuki, C. Barillà, B.Wang, Y. Cheng, H. Bihler, K. Coote, B. Davis, M. Mense, G. Solomon, E. Sorscher. Demonstration of pharmacologic N1303 K CFTR rescue in heterologous and human tissue-based model systems. Pulmonology Supp Volume 20, Supplement 2 (Abstract 638), 2021	Poster
C. Barillà, S. Suzuki, A. Rab, B. Wang, J. Hong, W. Driggers, A. Streby, R. Feldman, R. Linnemann, G. Solomon, A. Stecenko, E. Sorscher, B. Davis. Development of an iPSC-based airway epithelial platform for evaluating patient-specific responses to modulators. Pulmonology Supp Volume 20, Supplement 2 (Abstract 667), 2021	Poster
J. Corcoran, C. Campbell, L. Bray, J.Brown, B.Woods, S. Ladores. Fertility preservation: Thematic analysis of interviews with partners of women with cystic fibrosis. Pulmonology Supp Volume 20, Supplement 2 (Abstract 228), 2021	Poster
S. Ladores, J. Corcoran, C. Campbell, L. Bray, J. Brown, B. Woods, P. Li. State of fertility preservation counseling: Knowledge, experiences, and preferences of partners of women with cystic fibrosis. Pulmonology Supp Volume 20, Supplement 2 (Abstract 230), 2021	Poster
O. Stransky, M. Pam, S. Ladores, M. Birru Talabi, S. Borrero, E. Godfrey, A. Roe, G. Sawicki, L. Zuckerwise, L. Mentch, J. Taylor-Cousar, R. Jain, T. Kazmerski. Engaging stakeholders in the development of a reproductive goals decision aid for women with cystic fibrosis. Pulmonology Supp Volume 20, Supplement 2 (Abstract 100), 2021	Poster
C. Margaroli, J. Koff, R. Tirouvanziam, A. Gaggar. EGFR signaling modulates the pathological adaptation of neutrophils recruited to CF airways. Pulmonology Supp Volume 20, Supplement 2 (Abstract 365), 2021	Poster
K. Genschmer, A. Gaggar, J. Blalock. Neutrophil-derived proteolytic extracellular vesicles in CF lung disease. Pulmonology Supp Volume 20, Supplement 2 (Abstract 380), 2021	Poster
G. Oates, R. Geurs, C. Mims, R. Bergquist, A. Hager, H. Gutierrez. A mobile health platform for pediatric cystic fibrosis: Impact on patient-reported outcomes and patient-centered care. Pulmonology Supp Volume 20, Supplement 2 (Abstract 275), 2021	Poster
J. Bailey, G. Brown, M. Corbera-Hincapie, C. Clemm, E. Dasenbrook, D. Durham, G. Oates, K. Reno, S. Sapp, M. Schechter, K. Robinson. Food insecurity in the cystic fibrosis care center network during COVID-19: Prevalence, screening, and interventions. Pulmonology Supp Volume 20, Supplement 2 (Abstract 337), 2021	Poster
A. Saulitis, S. Noyes, S. Gomez, L. Thomas, M. Britto, M. Seid. Drop-in QI: Model for improvement education in the CF learning network. Pulmonology Supp Volume 20, Supplement 2 (Abstract 84), 2021	Poster
R. Jain, A. Keller, M. Lee, N. West, T. Kazmerski, M. Aitken, A. Roe, D. Hadjiliadis, A. Uluer, S. Mody, P. Flume, L. Bray, J. Taylor-Cousar. Effect of pregnancy on lung function: Impact of CFTR modulators. Pulmonology Supp Volume 20, Supplement 2 (Abstract 169), 2021	Poster
J. Guimbellot, K. Ryan, J. Anderson, Z. Liu, J. Natt, L. Kersh, E. Acosta. Epithelial cell pharmacokinetics of ivacaftor. Pulmonology Supp Volume 20, Supplement 2 (Abstract 175), 2021	Poster
W. Nesser, S. Snyder, K. Driscoll, A. Modi. Rasch analysis of the Caregiver Quality of Life Cystic Fibrosis Scale. Pulmonology Supp Volume 20, Supplement 2 (Abstract 277), 2021	Poster
C. Mims, K. Lachowicz, V. Anderson, S. Self, H. Gutierrez. Increasing access to educational media: Use of dynamic QR codes on a "CF Across the Lifespan" banner. Pulmonology Supp Volume 20, Supplement 2 (Abstract 325), 2021	Poster
C. Mims, T. Harris, H. Gutierrez. Innovative technology for disseminating information to families and people with CF. Pulmonology Supp Volume 20, Supplement 2 (Abstract 326), 2021	Poster

Presentation / Award	Category
D. Laucirica, C. Schofield, S. McLean, C. Margaroli, P. Agudelo-Romero, S. Stick, R. Tirouvanziam, A. Kicic, L. Garratt. Pseudomonas aeruginosa infection modulates primary granule exocytosis. Pulmonology Supp Volume 20, Supplement 2 (Abstract 348), 2021	Poster
M. Terry, J. Keith, A. Oden, S. Birket. Muc5b knockdown alters chronic infection outcomes in CFTR-KO rats. Pulmonology Supp Volume 20, Supplement 2 (Abstract 401), 2021	Poster
J. Baty, S. Stoner, J. Huffines, J. Scoffield. An oral commensal modulates the host immune response to Pseudomonas aeruginosa infection. Pulmonology Supp Volume 20, Supplement 2 (Abstract 497), 2021	Poster
G. Bollar, J. Keith, A. Oden, M. Kiedrowski, S. Birket. Establishing a mutant for modeling Staphylococcus aureus small colony–variant airway infection in cystic fibrosis. Pulmonology Supp Volume 20, Supplement 2 (Abstract 507), 2021	Poster
M. Easter, M. Hirsch, E. Harris, E. Helton, G. Bollar, S. Birket, J. Barnes, S. Krick. Accelerated aging pathways are activated in cystic fibrosis airway disease. Pulmonology Supp Volume 20, Supplement 2 (Abstract 566), 2021	Poster
Y. Mao, M. Icyuz, S. Santos, A. Rab, J. Hong, E. Sorscher, J. Hartman, K. Oliver. Discovery of novel epistatic interactions that influence CFTR folding trajectory. Pulmonology Supp Volume 20, Supplement 2 (Abstract 614), 2021	Poster
Z. Yang, F. Jiang, J. Wehby, A. Aleksandrov, S. Estabrooks, J. Brodsky, M. Hirschi, W. Balch, C. Sabusap, L. Plate, X. Fang, T. Hwang, N. Soya, G. Lukacs, C. Wang, S. Vorobiev, J. Hunt, C. Brouillette, J. Kappes. CFTR protein production core: Availability of purified full-length wildtype and disease-mutant CFTR proteins and new experimental data revealing insights into CFTR function and disease mechanism. Pulmonology Supp Volume 20, Supplement 2 (Abstract 622), 2021	Poster
S. Vorobiev, C. Wang, Z. Yang, F. Jiang, J. Wehby, A. Aleksandrov, O. Clarke, R. Grassucci, K. Wong1, J. Riordan, C. Brouillette, I. Urbatsch, J. Kappes, J. Frank, J. Hunt. VX-770 does not efficiently activate human CFTR in digitonin. Pulmonology Supp Volume 20, Supplement 2 (Abstract 626), 2021	Poster
S. Aller, B. Sumeet, G. Hemminger, J. Forrest. A nonolfactory shark adenosine receptor activates CFTR with unique pharmacology and structural features. Pulmonology Supp Volume 20, Supplement 2 (Abstract 636), 2021	Poster
K. Keeling, A. Siddiqui, J. Echols, V. Havasi, L. Fu, Y. Edwards. Exploring nonsense-mediated mRNA decay of CFTR as a therapeutic target. Pulmonology Supp Volume 20, Supplement 2 (Abstract 655), 2021	Poster
D. Bedwell. “Small molecule approaches to suppress CFTR nonsense mutations”	Symposium
GM. Solomon. “Biomarkers of CFTR activity”	Symposium
E. Harris. “Altered mucin sialylation results in delayed mucociliary transport in cystic fibrosis”	Workshop
Philadelphia, PA: November 3-November 5, 2022	
M. Stalvey, R. Walega, S. Rowe, D. Nichols, D. Stefanovski, A. Kelly. Promise: Glucose excursion and insulin secretion after 12 to 18 months of highly effective modulator therapy. Pulmonology Supp Volume 21, Supplement 2 (Abstract 15), 2022	Poster
M. Gunnett, C. Mims, H. Gutierrez, S. Self, J. Guimbellot. Outcomes of children with cystic fibrosis transmembrane conductance regulator–related metabolic syndrome. Pulmonology Supp Volume 21, Supplement 2 (Abstract 23), 2022	Poster
R. Patil, A. Magaret, R. Jain, J. Taylor-Cousar, M. Stalvey, T. Kazmerski. Impact of early growth trajectories and cystic fibrosis transmembrane conductance regulator modulator therapy on puberty in cystic fibrosis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 45), 2022	Poster

Presentation / Award	Category
K. Bliton, G. Oates. Vaping and vaping exposure in children, adolescents, and young adults with cystic fibrosis: Prevalence and outcomes. Pulmonology Supp Volume 21, Supplement 2 (Abstract 56), 2022	Poster
F. Asfour, J. Bailey, S. Allen, D. Gamory, D. Jennings, M. Lester, S. Thompson, A. Uluer, P. Mertz, C. Hovater, K. Sabadosa. Development of a national cystic fibrosis patient and caregiver experience of care survey. Pulmonology Supp Volume 21, Supplement 2 (Abstract 80), 2022	Poster
J. Bailey, D. Gamory, F. Asfour, S. Allen, K. Sabadosa. Results from the National Cystic Fibrosis Foundation Experience of Care survey. Pulmonology Supp Volume 21, Supplement 2 (Abstract 81), 2022	Poster
J. Cassidy, R. List, M. Akers, D. Albon, J. Cogen, B. Evangelista, B. Gamel, L. Greene, C. Joinson, M. Manville, S. McNamara, L. Thomas, C. Salaman, L. Williamson, J. Vajda, T.Ong. Advancing patient-family partnership through shared co-production tools in two cystic fibrosis learning network sites. Pulmonology Supp Volume 21, Supplement 2 (Abstract 90), 2022	Poster
L. Thomas, B. Gamel, S. Noyes, R. Lochte, A. Saulitis, T. Ong. Cystic Fibrosis Learning Network Learning Structure for Multicenter Spread of Co-Production and Timely Patient Registry Data Entry Practices. Pulmonology Supp Volume 21, Supplement 2 (Abstract 91), 2022	Poster
T. Poore, J. Peabody-Lever, S. Hussain, H. Kim, W. Harris, S. Phillips, S. Rowe. Development and characterization of pulmonary disease in G551D ferret model on chest computed tomography imaging. Pulmonology Supp Volume 21, Supplement 2 (Abstract 113), 2022	Poster
G. Oates, E. Baker, V. Raju, W. Harris, S. Rowe. Tobacco smoke exposure reduces the clinical efficacy of ivacaftor: Results from the G551D Observational Trial. Pulmonology Supp Volume 21, Supplement 2 (Abstract 137), 2022	Poster
G. Solomon, C. Fernandez-Petty, R. Joseph, K. Vijaykumar, J. Wade, D. Nichols, G. Tearney, S. Rowe. **I**n vitro responses of F508DEL human nasal epithelial cells correlate with clinical improvement with elexacaftor/tezacaftor/ivacaftor. Pulmonology Supp Volume 21, Supplement 2 (Abstract 154), 2022	Poster
K. Vijaykumar, H. Leung, A. Barrios, S. Donaldson, D. Nichols**,** S. Rowe, G. Tearney, G. Solomon. Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 155), 2022	Poster
F. Ratjen, J. Pittman, A. Paynter, M. Skalland, S. Heltshe, J. Xie, L. Couture, D. Nichols, S.Rowe, M. Rosenfeld, T. Promise Group. Effectiveness of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: The pediatric PROMISE study. Pulmonology Supp Volume 21, Supplement 2 (Abstract 173), 2022	Poster
J. Guimbellot,J. Natt, K. Ryan, A. Dowell, K. Odem-Davis, M. Konstan, E. Zemanick, N. Mayer-Hamblett, E. Acosta. Concentrations of elexacaftor/tezacaftor/ivacaftor in the cystic fibrosis population: Interim analysis of the CHEC-Pharmacokinetics study. Pulmonology Supp Volume 21, Supplement 2 (Abstract 261), 2022	Poster
J. Anderson, D. Brittney, G. Giang, A. Smith, C. Lee, K. Parker, H. Searcy, K. Benner, N. Limdi, J. Guimbellot. Pharmacogenomics in people with cystic fibrosis: A personalized medicine approach. Pulmonology Supp Volume 21, Supplement 2 (Abstract 263), 2022	Poster
E. Baker, H. Gutierrez, S. Gamble, G. Oates. Effect of an oscillatory positive expiratory pressure device on lung function change in children with cystic fibrosis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 272), 2022	Poster
C. Snell, I. Bailey, D. Sandage, B. Ertman, A. Alpern, B. Smith, B. Garcia, G. Sawicki, A. Uluer. Development and validation of the Cystic Fibrosis Stress Questionnaire: A cystic fibrosis–specific measure of perceived stress. Pulmonology Supp Volume 21, Supplement 2 (Abstract 291), 2022	Poster
E. McWilliams, D. Yablon, R. Kesim, R. Ge, A. Donkoh, M. Abdelnour, C. George, E. Muther, G. Oates, K. Riekert, M. Sathe, G. Sawicki, C. Snell, M. Phillips, C. Eaton. A systematic review of behavioral change techniques in mobile health interventions for adherence or self-management:	Poster

Presentation / Award	Category
application to people with cystic fibrosis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 303), 2022	
A. Franciosi, A. Tanzler, J. Goodwin, P. Wilcox, G. Solomon, A.Faro, N. McElvaney, D. Downey, B. Quon. Inter-clinician diagnostic concordance assessing adults presenting with possible cystic fibrosis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 360), 2022	Poster
M. Terry, J. Keith, A. Oden, S. Birket. Preinfection knockdown of Muc5b reduces severity of chronic Pseudomonas aeruginosa infection in the cystic fibrosis transmembrane conductance regulator knockout rat. Pulmonology Supp Volume 21, Supplement 2 (Abstract 387), 2022	Poster
J. Wykoff, K. Shaffer, K. Araba, M. Markovetz, J. Patarin, M. Robert de Saint vincent, S. Donaldson, C. Ehre. Rapid viscoelastic characterization of airway mucus using a benchtop rheometer. Pulmonology Supp Volume 21, Supplement 2 (Abstract 388), 2022	Poster
D. Cho, S. Zhang, A. Lazrak, D. Skinner, D. Lim, J. Grayson, S. Matalon, S. Rowe, B. Woodworth. Hypoxia-induced cystic fibrosis transmembrane conductance regulator dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 410), 2022	Poster
C. Margaroli, K. Yuan, A. Christenson, A. Gaggar, S. Duncan. Pathological autoimmune responses in cystic fibrosis exacerbation. Pulmonology Supp Volume 21, Supplement 2 (Abstract 448), 2022	Poster
G. Bollar, J. Keith, A. Oden, M. Kiedrowski, S. Birket. Staphylococcus aureus small colony variant infection pathology in the cystic fibrosis rat lung. Pulmonology Supp Volume 21, Supplement 2 (Abstract 456), 2022	Poster
C. Billiot, N. Lindgren, W. Swords, M. McDaniel. Achromobacter xylosoxidans as a cystic fibrosis–related pathogen. Pulmonology Supp Volume 21, Supplement 2 (Abstract 460), 2022	Poster
D. Cho, D. Skinner, D. Lim, S. Zhang, J. Grayson, W. Swords, E. Rocha, B. Woodworth, M. Kiedrowski, R. Hunter. Acetate and propionate metabolism by Pseudomonas aeruginosa contributes to significant sinus inflammation in a rabbit model of sinusitis. Pulmonology Supp Volume 21, Supplement 2 (Abstract 473), 2022	Poster
M. Hirsch, E. Hughes, M. Easter, S. Bollenbecker, S. Birket, J. Barnes, M. Kiedrowski, S. Krick. Chronic Pseudomonas aeruginosa infection in a cystic fibrosis in vitro model. Pulmonology Supp Volume 21, Supplement 2 (Abstract 488), 2022	Poster
K. Shaffer, J. Wykoff, K. Araba, E. Worthington, R. Tarran, R. Pickles, C. Ehre. Cystic fibrosis transmembrane conductance regulator modulator therapy increases viral mobility in primary cystic fibrosis airway cultures infected with respiratory syncytial virus. Pulmonology Supp Volume 21, Supplement 2 (Abstract 498), 2022	Poster
N. Evans, K. Valladares, P. Pukkanasut, S. Velu, J. Scoffield. Small-molecule interference of the Pseudomonas aeruginosa glyoxylate pathway. Pulmonology Supp Volume 21, Supplement 2 (Abstract 533), 2022	Poster
N. Lindgren, T. Ptacek, L. Novak, M. McDaniel, W. Swords. Genomic diversity of nontypeable Haemophilus influenzae affects colonization and persistence in vivo. Pulmonology Supp Volume 21, Supplement 2 (Abstract 542), 2022	Poster
E. Hughes, M. Kiedrowski. Influence of nutrient availability in the cystic fibrosis airways on Staphylococcus aureus growth. Pulmonology Supp Volume 21, Supplement 2 (Abstract 543), 2022	Poster
T. Poore, H. Hathorne, E. Macomb, S.Rowe. Changes in total immunoglobulin E levels and fungal acquisition in people with cystic fibrosis before and after elexacaftor/tezacaftor/ivacaftor initiation. Pulmonology Supp Volume 21, Supplement 2 (Abstract 572), 2022	Poster
G. Solomon, S. Suzuki, H. Hathorne, C. Barilla, B. Wang, A.Rab C. Manfredi, D. Joshi, J. Brewington, A. Stecenko, W. Driggers, S. Bai, E. Hunter, A. Streby, J. Hong, K. Odem-Davis, B. Davis, E. Sorscher, R. Linnemann. Focused clinical trials of modulator response for rare cystic fibrosis genotypes. Pulmonology Supp Volume 21, Supplement 2 (Abstract 606), 2022	Poster

Presentation / Award	Category
K. Thrasher, X. Xue, D. Benson, J. Chen, M. Renfrow, K. Keeling, S. Rowe, D. Bedwell. Evaluating the mechanism of amino acid insertion upon readthrough of cystic fibrosis transmembrane conductance regulator nonsense mutations. Pulmonology Supp Volume 21, Supplement 2 (Abstract 610), 2022	Poster
D. Bedwell, M. Du, J. Yoon, J. Sharma, V. Mutyam, Y.Li, J. Chen, K. Thrasher, L.Fu, N. Peng, L. Tang, C. Augelli-Szafran, K. Keeling, M. Mense, S.Rowe. Understanding synergy in nonsense suppression therapy for cystic fibrosis transmembrane conductance regulator nonsense mutations. Pulmonology Supp Volume 21, Supplement 2 (Abstract 613), 2022	Poster
A. Siddiqui, J. Echols, L. Fu, K. Keeling. Messenger ribonucleic acid binding proteins PTBP1 and HNRNPL modulate cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid abundance. Pulmonology Supp Volume 21, Supplement 2 (Abstract 637), 2022	Poster
S. Rowe, J. Chen, M.Du, Y.Li, N. Peng, L. Tang, V. Mutyam, J. Sharma, K. Thrasher, L.Fu, K. Liu1, B. Mathew, K. Rodzinak, R. Bostwick, K. Keeling, M. Suto, C. Augelli-Szafran, D. Bedwell. A novel eRF1 degrader induces translational readthrough of cystic fibrosis transmembrane conductance regulator nonsense mutations to therapeutically relevant levels in combination with aminoglycosides. Pulmonology Supp Volume 21, Supplement 2 (Abstract 645), 2022	Poster
R. Mancinone, L. Lowe, E. Gaines, S. Santos, J. Rodgers, E. Sorscher, J. Hartman IV. Functional analysis of elexacaftor/tezacaftor/ivacaftor-refractory class II mutations by yeast phenomic profiling. Pulmonology Supp Volume 21, Supplement 2 (Abstract 649), 2022	Poster
T. White, S. Santos, M. Icyuz, W. Wang, A.Rab, J. Hong, E. Sorscher, J. Hartman, IV, K. Oliver. Ribosomal silencing confers cystic fibrosis transmembrane conductance regulator nonsense suppression and is synergistic with highly effective modulators. Pulmonology Supp Volume 21, Supplement 2 (Abstract 650), 2022	Poster
J. Goeckeler-Fried, S. Estabrooks, Z. Yang, X. Zeng, P. Cantrell, N. Yates, J. Kappes, J. Brodsky. Targeting CFTR ubiquitination to augment therapeutic strategies. Pulmonology Supp Volume 21, Supplement 2 (Abstract 653), 2022	Poster
L. Rasmussen, M. Mazur, S.Rowe, V. Raju. The PDE4 inhibitor apremilast enhances benefits of cystic fibrosis transmembrane conductance regulator modulators in vitro and in vivo. Pulmonology Supp Volume 21, Supplement 2 (Abstract 661), 2022	Poster
J. Chen, K. Thrasher, L. Fu, W.Wang, S. Aghamohammadzadeh, H. Wen, L. Tang, K. Keeling, E. Libby, D. Bedwell, S.Rowe. Synthetic aminoglycoside ELX-02 induces readthrough of cystic fibrosis transmembrane conductance regulator–G550X, producing super-functional protein that can be further enhanced by cystic fibrosis transmembrane conductance regulator correctors. Pulmonology Supp Volume 21, Supplement 2 (Abstract 691), 2022	Poster
Kari Thrasher (graduate student). “Evaluating the mechanism of amino acid insertion upon readthrough of CFTR nonsense mutations” (TPS04.4)	Thematic Poster Session
Emily Hughes (graduate student). Influence of Nutrient Availability in the Cystic Fibrosis Airways on *Staphylococcus aureus* Growth (RFPT12.5)	Rapid Fire Poster Talk
Steve Rowe. “A Novel eRF1 Degrader Induces Translational Readthrough of CFTR Nonsense Mutations to Therapeutically Relevant Levels in Combination with Aminoglycosides” (RFPT10.5)	Rapid Fire Poster Talk
G. Marty Solomon. “Focused clinical trials of modulator response for rare cystic fibrosis genotypes” (RFPT09.1)	Rapid Fire Poster Talk
Mikayla Terry (graduate student). “Pre-Infection Knockdown of Muc5b Reduces Severity of Chronic *Pseudomonas aeruginosa* Infection in the CFTR-KO Rat” (RFPT01.4)	Rapid Fire Poster Talk
Elizabeth Baker. “Effect of Aerobika®, an Oscillatory Positive Expiratory Pressure Device, on Lung Function in Pediatric Patients with CF: A Longitudinal Analysis” (RFPT09.3)	Rapid Fire Poster Talk

Presentation / Award	Category
Gabriela Oates. “Tobacco smoke exposure reduces the clinical efficacy of ivacaftor: Results from the G551D observational trial (GOAL)” (W02.2)	Workshop
Jianguo Chen. “Synthetic aminoglycoside ELX-02 induces readthrough of CFTR-G550X producing super-functional protein that can be further enhanced by CFTR correctors” (W04.1)	Workshop
Jennifer Guimbellot. “Updates in CF pharmacotherapy: concentrations of elexacaftor/tezacaftor/ivacaftor in the cystic fibrosis population: interim analysis of the CHEC-Pharmacokinetics study” (W16.4)	Workshop
Michael Stalvey, “Promise: glucose excursion & insulin secretion following 12-18 months of highly effective modulator therapy” (W33.1)	Workshop
Do-Yeon Cho. "Acetate and propionate metabolism by Pseudomonas aeruginosa contributes to significant sinus inflammation in a rabbit model of sinusitis" (W24.1)	Workshop
Bradford Woodworth. "Hypoxia-induced CFTR dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis" (W20.2)	Workshop
Lawrence Rasmussen (postdoctoral trainee). “PDE4 Inhibitor, Apremilast, Enhances Benefits of CFTR Modulators in vitro and in vivo” (W08.4)	Workshop
Gretchen Bollar (graduate student). “*Staphylococcus aureus* small colony variant infection pathology in the cystic fibrosis rat lung” (W24.2)	Workshop
Kyle Bliton (fellow). “Vaping and vaping exposure in children, adolescents, and young adults with cystic fibrosis: prevalence and outcomes.” (W07.3)	Workshop
Leslie Miller. "Adjustment, grief and loss as we age" (S08)	Symposium
John Lowman. “A multidisciplinary approach to the benefits of exercise for people with CF” (S19.3)	Symposium
John Lowman. ”Is exercise detrimental to nutritional status in CF?” (S30.3)	Symposium
G. Marty Solomon. “Lessons learned from the PROMISE of elexacaftor/tezacaftor/ivacaftor” (S15.1)	Symposium
G. Marty Solomon. “Considerations for design and outcomes measures for clinical trial of gene/mRNA-based therapies” (S01.1)	Symposium
Michael Stalvey. Specialist Treatment (S33.4)	Symposium
Steve Rowe. “Hope for all: addressing the needs of those with untreated CF mutations” (P1)	Plenary
Mikayla Terry (graduate student). Winner, Junior Best Investigator, Basic Science	Award
Gretchen Bollar (graduate student). Finalist, Junior Best Investigator, Basic Science	Award
Lawrence Rasmussen (postdoctoral trainee). Semi-finalist, Junior Best Investigator, Basic Science	Award
Kim Keeling. Molecular Mechanisms to Overcome CFTR Nonsense & Other Rare Variants (TPS04)	Chair, Thematic Poster Session
Stefanie Krick. Clinical – Pulmonary (RFPT05).	Chair, Rapid Fire Poster Talk

Presentation / Award	Category
Jennifer Guimbellot. Impact of HEMT on Health Outcomes Across the Spectrum of Disease (TPS01)	Chair, Rapid Fire Poster Talk
Julianna Bailey. Health is More Than a Number (W13)	Chair, Workshop
Megan Kiedrowski. Best Junior Investigator in Basic Sciences Competition	Judge and Panelist, Junior Investigator Sessions
Phoenix, AZ: November 2-November 4, 2023	
M. Mullins, G. Caleb, L. Cohen, G. Ratti, C. Mingora, P. Flume, S. Krick, K. Vijaykumar, B. Garcia. Spontaneous changes to airway microbiology after initiation of elexacaftor-tezacaftor-ivacaftor in people with advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 14).	Poster
T. Poore, S. Leal, R. Chellappan, L. Schaefers, J. Campos-Gomez, A. Nguyen, L. Lam, S. Rowe, S. Birket. Novel detection and infection modeling of Aspergillus fumigatus in pyocyanin-stimulated primary airway epithelium and mucus models. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 47).	Poster
M. Terry, J. Keith, A. Oden, S. Birket. Spontaneous infection in the cystic fibrosis rat model is linked to gastrointestinal obstruction. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 48).	Poster
G. Bollar, J. Keith, A. Oden, T. Poore, S. Birket. Chronic Staphylococcus aureus and Pseudomonas aeruginosa coinfection causes structural lung damage in the adult cystic fibrosis rat. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 62).	Poster
S. Morgan, R. Cramer, E. Vesely, W.Ni, G. Hong, S. Salipante, J. Clancy, S. Rowe, D. Nichols, P. Singh. Sputum density of Aspergillus fumigatus markedly declines after treatment with elexacaftor-tezacaftor-ivacaftor. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 64).	Poster
C. Sebastian, R. Boone, J. Harris, M. Kiedrowski. Determining effects of antibiotic treatments on early-stage colonizers in the cystic fibrosis airway environment. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 75).	Poster
D. Cho, D. Skinner, S. Zhang, D. Lim, M. Kiedrowski, B. Woodworth. Clinical Pseudomonas aeruginosa isolates from cystic fibrosis sinusitis prevent flagellin-mediated immune recognition. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 102).	Poster
S. Donaldson, T. Corcoran, J. Pilewski, B. Laube, P. Mogayzel, A. Ceppe, J.Wu, K. Zeman, S. Rowe, D. Nichols, A. Gifford, W. Bennett, N. Hamblett. Effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in people with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: The SIMPLIFY-MCC Study. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 113).	Poster
M. Rosenfeld, C. O'Rourke, P. Vu, A. De Fermin Cortes, A. Kelly, D. Nichols, J. Pittman, F. Ratjen, G. Solomon, N. Hamblett, S. Heltshe. Is home spirometry accurate? Comparison between home and office spirometry in the PROMISE study. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 124).	Poster
M. Hanafy, C. Fernandez-Petty, R. Joseph, K. Vijaykumar, G. Tearney, S. Rowe, G. Solomon. In vitro responses of F508DEL human nasal epithelial cells correlate with clinical improvement with elexacaftor-tezacaftor-ivacaftor. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 131).	Poster

Presentation / Award	Category
P. McNally, G. Solomon, D. Nichols, S. Rowe, F. Ratjen, M. Rosenfeld, A. Kelly, L. Kirwan, J. Davies, S. Heltshe. Factors associated with significantly corrected sweat chloride in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—results from the PROMISE and RECOVER studies. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 141).	Poster
D. Moncada-Giraldo, V. Giacalone, J. Alvarez, C. Margaroli, V. Tangpricha, R. Tirouvanziam. High-dose vitamin D treatment of cystic fibrosis pulmonary exacerbations modulates the correlation profile of plasma immune mediators. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 143).	Poster
A. Goriounova, J. Wrennall, A. Gaggar, R. Tarran. Normal, but not cystic fibrosis, sputum inhibits pro-inflammatory Orai1 Ca2+ signaling. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 155).	Poster
Y. Soto-Vazquez, J. Koff, R. Tirouvanziam, A. Gaggar, C. Margaroli. Epidermal growth factor receptor–inducible nitric oxide synthase signaling axis modulates bacterial killing in cystic fibrosis airway neutrophils. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 172).	Poster
D. Otuya, R. Joseph, Z. Liu, M. Hanafy, K. Vijaykumar, S. Raju, S. Rowe, G. Tearney, G. Solomon. Development and initial evaluation of a platform to measure in vivo short circuit current to detect CFTR functional restoration. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 191).	Poster
M. Terry, J. Keith, G. Bollar, I. Doty, A. Oden, S. Birket. Ivacaftor ameliorates acute but not chronic Pseudomonas aeruginosa infection in cystic fibrosis rats. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 212).	Poster
A. Allen, D. Stanford, L. Rasmussen, L. Antony, A. Challa, S. Raju. Characterization of a novel rat model of W1098X CFTR generated by Crispr-Cas9. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 224).	Poster
L. Antony, L. Rasmussen, D. Stanford, A. Allen, S. Raju. Alcohol impairs airway CFTR function and mucociliary clearance, but PDE4 inhibitor roflumilast offers partial protection. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 226).	Poster
D. Cho, S. Zhang, D. Lim, D. Skinner, S. Rowe, B. Woodworth. Glutathione and bicarbonate nanoparticles improve mucociliary transport in cystic fibrosis epithelia. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 229).	Poster
K. Keeling, A. Siddiqui, A. Saxena, J. Echols, L. Fu. Regulation of CFTR mRNA abundance by nonsense mediated mRNA decay. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 234).	Poster
R. Linnemann, G. Solomon, S. Suzuki, A. Rab, C. Barill, A. Stecenko, W. Hunt, A.Westbrook, S. Bai, B. Buehler, R. Rich, E. Hunter, A. Streby, J. Hong, B. Davis, E. Sorscher. An open-label trial to evaluate elexacaftor-tezacaftor-ivacaftor and induced pluripotent stem cell–derived model systems in individuals with residual CFTR activity. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 242).	Poster
G. Solomon, R. Linnemann, R. Rich, A. Streby, E. Hunter, B. Buehler, W. Hunt, C. McNicholas, S. Bai, A. Westbrook, S. Suzuki, B. Davis, E. Sorscher. Interim results of an open-label trial to evaluate elexacaftor-tezacaftorivacaftor in individuals with cystic fibrosis and an N1303K mutation who are not eligible for modulator treatment. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 252).	Poster
R. Mancinone, E. Gaines, S. Santos, J. Rodgers, E. Sorscher, J. Hartman. Pharmaco-phenomic modeling of elexacaftor-tezacaftor-ivacaftor–refractory CFTR alleles. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 262).	Poster
K. Thrasher, J. Ekstrom, K. Keeling, D. Bedwell. eRF1 degrader SRI-41315 triggers the ribosome quality control E3 ligase Network. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 266).	Poster
K. Thrasher, J. Chen, L. Fu, X. Xue, D. Benson, J. Ekstrom,K. Keeling, M. Renfrow, S. Rowe, D. Bedwell. Identifying the amino acid(s) inserted upon premature termination codon readthrough and their effect on CFTR functionality. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 268).	Poster

Presentation / Award	Category
J. Campos-Gomez, S. Shukla, S. Parker, P. Chivukula, S. Boehme, D. Geller. LUNAR-CFTR mRNA replacement therapy restores CFTR expression and function in human bronchial epithelial cells. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 270).	Poster
M. Du, Y. Dai, L. Fu, J. Tillotson, C. Augelli-Szafran, K. Keeling, S. Rowe, D. Bedwell. Synergistic effects on readthrough of G542X CFTR by combining eRF1 and eRF3 degraders. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 271).	Poster
C. Barill, A. Rab, S. Suzuki, R. Bertrand, S. Winkler, S. Ponnaluri, E. Hunter, A. Streby, C. Driggers, B. Buehler, J. Hong, C. McNicholas, R. Linnemann, G. Solomon, A. Stecenko, E. Sorscher, B. Davis. Induced pluripotent stem cell–based airway epithelial platform for investigating personalized responses to CFTR modulators. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 280).	Poster
W. Wang, L. Fu, C. Martin, S. Rowe, S. Aller. CFTR-R933 mutations reduce channel opening but still permit potentiation by ivacaftor. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 295).	Poster
C. Le, C. Martin, Z. Yang, J. Kappes, S. Aller. Mutations at the rare cystic fibrosis site arginine-933 form folded CFTR by cryogenic electron microscopy. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 306).	Poster
K. Vijaykumar, D. Otuya, N. Dechene, H. Hathorne, J. Anderson, B. Liu, G. Solomon, G. Tearney, S. Rowe. Validation of a novel integrated image guided potential difference system to facilitate conduct of lower airway potential difference. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 312).	Poster
S. Rowe, J. Chen, B. Mathew, O. Moukha-Chafiq, J. Tillotson, K. Rodzinak, M. Du, Y. Li, N. Peng, L. Tang, K. Thrasher, L. Fu, K. Liu, R. Bostwick, K. Keeling, C. Augelli-Szafran, D. Bedwell. Novel eRF3 degrader monotherapy induces translational readthrough of CFTR nonsense mutations at therapeutically relevant levels. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 318).	Poster
C. Wang, Z. Yang, A. Aleksandrov, S. Vorobiev, B. Loughlin, Z. Rich, O. Clarke, F. Jiang, C. Brouillette, I. Urbatsch, J. Frank, G. Lukacs, C. Govaerts, J. Kappes, J. Hunt. Cryogenic electron microscopy studies of human CFTR folding and conformational dynamics elucidate a novel potentiator binding site in the nucleotide binding domains that supports an alternative channel gating mechanism. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 335).	Poster
G. Kaur, D. Brown, B. Wilk, M. Gajapathy, T. Mamidi, S. Hutchins, S. Murali, C. Birch, H. Lai, P. Farrell, E. Worthey. Unraveling the complexity of cystic fibrosis: genetic modifiers and their roles in cystic fibrosis pathogenesis. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 344).	Poster
S. Ladores, B.Woods, D. Belay, L.Washington, L.Bray. Lived experiences of Black individuals with cystic fibrosis. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 381).	Poster
B. Woods, L. Bray, P. Li, T. Kazmerski, C. Hovatar, S. Ladores, S. Campbell. Development of a fertility preservation telehealth counseling intervention for men with cystic fibrosis: patient and provider perspectives. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 382).	Poster
C. Mims, S. Self, V. Anderson, S. Gamble, F. Ruiz, N. Patel, A. Faro, H. Gutierrez. Effective approach to improve cystic fibrosis care delivery in resource-challenged regions. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 389).	Poster
S. Ladores, B. Woods, P. Li, S. Campbell, T. Kazmerski, C. Hovatar, L. Bray. Implementation and evaluation of a fertility preservation telehealth counseling intervention for men with cystic fibrosis. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 392).	Poster
T. Kazmerski, C.Moy, E. Aliaj, J. Hudson, B. Wright, M. Poranski, J. Sjoberg, J. Taylor-Cousar, A. Georgiopoulos, S. Ladores, A. Trimble, V. Tangpricha, F. Naz Khan, R. Ramasamy, D. Velez Leitner, N.West, A. Wilson, A. Keller, O. Stransky, R. Delos Santos, R. Jain. “SHARING” sexual and reproductive health priorities of adults with cystic fibrosis and caregivers. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 393).	Poster

Presentation / Award	Category
N. Lindgren, A. Chalamalla, B. Garcia, S. Krick, J. Bergeron, H. Sadeghi, D. Schellhase, K. Ryan, A. Dowell, E. Acosta, J. Guimbellot. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 425).	Poster
J. Guimbellot, A. Dowell, K. Ryan, J. Anderson, E. Acosta. Ivacaftor metabolites in epithelia. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 440).	Poster
G. Oates, R. Geurs, C. Mims, S. Gamble, E. Baker, B.Woods, E. Coleman, S. Ladores. Clinical Effort Against Smoke Exposure in Cystic Fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 469).	Poster
R. Geurs, S. Niranjan, B. Woods, E. Coleman, S. Ladores, G. Oates. “It was all tailored around me”: qualitative evaluation of Clinical Effort Against Smoke Exposure in Cystic Fibrosis (CEASE-CF). Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 473).	Poster
L. Pitts, B. Woods, M. Polen, S. Ladores. Using hygge to promote wellness and coping with cystic fibrosis. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 474).	Poster
C. Snell, I. Bailey, D. Sandage, B. Ertman, M. Ryan, S. Dahlberg, A. Alpern, B. Smith, B. Garcia, G. Sawicki, A. Uluer. Validation of the Cystic Fibrosis Stress Questionnaire: a multisite study. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 495).	Poster
J. Duong, C. Pope, H. Hayden, C. Miller, S. Salipante, S. Rowe, G. Solomon, D. Nichols, L. Hoffman, M. Narkewicz, N. Green. Alterations in the fecal microbiota of patients with advanced cystic fibrosis–associated liver disease after 6 months of elexacaftortezacaftor-ivacaftor. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 528).	Poster
P. Suppakitjanusant, L. González Ramírez, M. Schor, E. Ivie, V. Tangpricha, V. Stallings, A. Goss, P. Sharma,W. Hunt, A. Stecenko, T. Ziegler, J. Alvarez. Adiposity is associated with glucose intolerance in adults with cystic fibrosis in the CFTR modulator era. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 529).	Poster
N. Ameen, D. dos Reis, P. Dastoor, A. Santos, M. Cohen, M. Donnelley, D. Parsons. Role of CFTR high expresser cells in cystic fibrosis intestinal disease. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 539).	Poster
J. Bailey, E. Baker, M. Schechter, K. Robinson, K. Powers, E. Dasenbrook, M. Hossain, G. Brown, C. Clemm, G. Oates. Food insecurity screening and local food access: contributions to nutritional outcomes at U.S. cystic fibrosis programs. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 544).	Poster
R. Bass, M. Stalvey, D. Nichols, S. Rowe, S. Schwarzenberg, S. Freedman, G. Solomon, A. Kelly. Lipid concentrations after 12 to 18 months of clinically prescribed elexacaftor tezacaftor ivacaftor—PROMISE substudy. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 579).	Poster
C. Chan, M. Shirley, R. Walega, S. Rowe, D. Nichols, D. Stefanovski, M. Stalvey, G. Solomon, A. Kelly. Glycemia and insulin secretion before and 2 years after elexacaftortezacaftor-ivacaftor initiation. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 581).	Poster
O. Stransky, G. Sawicki, S. Ladores, K. Hughan, N. West, R. Jain, J. Taylor-Cousar, V. Tangpricha, T. Kazmerski. Sexual and reproductive health knowledge, experiences, care use, and preferences of adolescent boys and men with cystic fibrosis. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 584).	Poster
E. Baker, J. Bailey, M. Schechter, J. Guimbellot, G. Oates. Social determinants of overweight and obesity in children with cystic fibrosis in the United States: a longitudinal analysis of Cystic Fibrosis Foundation Patient Registry data (2009-2019). Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 606).	Poster
G. Oates, E. Baker, W. Harris, J. Collaco, M. Schechter. Tobacco smoke exposure limits clinical benefit of elexacaftortezacaftor-ivacaftor: longitudinal analysis of Cystic Fibrosis Foundation Patient Registry data. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 615).	Poster

Presentation / Award	Category
S. Cheng, Y. Naito, S. Charman, H. Gutierrez, A. Jung, J. van Rens,A. Orenti, B. Karadag, A. Elbert, A. Stephenson. It takes a village: cystic fibrosis research beyond borders. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 616).	Poster
C. Castaños, M. Plubatsch, H. Giugno, A. Agustinho, N. Crespi, M. Raspini, C. Alasio, B. Soto Montesano, C. Mims, V. Anderson, S. Gamble, A. Faro, N. Patel, H. Gutierrez. Impact of effective cystic fibrosis center team training in a low- to-middle-income country. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 666).	Poster
J. Lawlor, K. Amos, L. Salter, J. Bailey, L. Miller, C. Crenshaw, D. Goodwin, M. Wainwright, G. Winter, S. Krick, B. Garcia. In-clinic oral glucose tolerance testing increases screening rates and patient satisfaction. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 690).	Poster
K. Lachowicz, V. Anderson, G. Marcum, W. Smith. Mental health screening: what happens next? . Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 700).	Poster
G. Brown, M. Backus, G. Coffman, M. DeGraaf, J. Ingle, A. Jones, L. McCoy, L. Peterson, S. Root, H. Polenakovik. Development and implementation of a standardized assessment tool to improve nutritional health of adults with cystic fibrosis—a quality improvement project. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 701).	Poster
B. Garcia, G. Caleb, J. Bailey, S. Krick. Efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in a cohort of older people with cystic fibrosis. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 724).	Poster
L. Cohen, G. Ratti, C. Mingora, P. Flume, B. Garcia, G. Caleb. A multicenter retrospective analysis of the clinical efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease: a follow-up study after 2 years of treatment. Journal of Cystic Fibrosis 22S3 (2023) S1–S408 (Abstract 725).	Poster
Kadambari Vijaykumar. RFPT07.5 – Validation of a novel integrated image guided potential difference system to facilitate conduct of lower airway potential difference	Rapid-Fire Poster Talk
Sigrid Ladores. RFPT05.6 – The lived experiences of African American individuals with cystic fibrosis	Rapid-Fire Poster Talk
Jennifer Guimbellot. TPS03.6 – Pharmacokinetic variability of CFTR modulators from standard and alternative regimens	Thematic Poster Session
Shingo Suzuki. TPS01.3 – Generation of airway basal stem cells from iPSC-derived airway progenitors: elucidation of signaling pathways responsible for basal cell maturation and proliferation	Thematic Poster Session
Justin Anderson. DG09 – Genetics for Research Coordinators	Discipline Group Session (Speaker)
John Lowman. DG23 – Pediatrics to geriatrics, from one to ninety-two	Discipline Group Session (Speaker)
Rachel Rich. DG21 – Technology in research	Discipline Group Session (Speaker)
Marty Solomon. LL10 – What are the most relevant clinical outcomes in PTAC-based trials	Lunch & Learn (Speaker)

Presentation / Award	Category
Brittany Woods. W09.5 – Development of a fertility preservation telehealth counseling intervention for males with cystic fibrosis: Patient and provider perspectives	Workshop
Christina Barilla. W31.4 – iPSC-based airway epithelial platform for investigating personalized responses to CFTR modulators	Workshop
Susan Birket. W21.4 – Ivacaftor ameliorates acute but not chronic Pseudomonas aeruginosa infection in CF rats	Workshop
Javier Campos-Gomez. W05.2 – LUNAR®-CFTR mRNA replacement therapy restores CFTR expression and function in human bronchial epithelial cells	Workshop
Marty Solomon. W22.2 – Interim results of an open-label trial to evaluate ETI in individuals with cystic fibrosis and an N1303K mutation who are not eligible for modulator treatment	Workshop
Gabriela Oates. W18.5 – Clinical Effort Against Smoke Exposure in Cystic Fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy	Workshop
Kari Thrasher. W31.3 – eRF1 degrader SRI-413115 triggers the ribosome quality control E3 ligase network	Workshop
Marty Solomon. S16.3 – Advancing personalized medicine: concepts and updates on theratyping	Symposium
Gabriela Oates. S29.3 – Socioeconomic factors and outcomes in people with CF	Symposium
Juliana Bailey. S26.2 – Update on weight management and enzymes – perspectives from the CF Foundation nutrition position pape	Symposium
S. Vamsee Raju. RT31 – Techniques to detect CFTR function in cells and tissues	Roundtable (Facilitator)
S. Vamsee Raju. RT36 – Impact of cigarette smoke on CFTR function	Roundtable (Facilitator)
Shingo Suzuki. RT52 – DNA editing-based approaches to optimizing rescue of CFTR	Roundtable (Facilitator)
Staci Self. PEP – Partnership Enhancement Program	PEP (Chair and Speaker)
Juliana Bailey. SC02 – Nuts and Bolts of Nutrition Research	Short Course (Chair)

Presentation / Award	Category
Kadambari Vijaykumar. RFPT07 – New & upcoming imaging techniques in CF	Rapid-Fire Poster Talk (Chair)
Heather Hathorne. DG09 – Genetics for Research Coordinators	Discipline Group Session (Chair)
Justin Anderson. DG09 – Genetics for Research Coordinators	Discipline Group Session (Chair)
Jianguo Chen. W05 – Rescuing CFTR premature truncation alleles: Basic biology & novel therapeutic strategies	Workshop (Chair)
Camilla Margaroli. W01 – Infection/inflammation models in CF	Workshop (Chair)
Spencer Poore. W20 – Microbial ecology in CF	Workshop (Chair)
Juliana Bailey. W06.1 – Food insecurity screening and local food access: Contributions to nutritional outcomes across CF programs in the United States	Workshop (Chair)
Kadambari Vijaykumar. W34 – Airway ions, fluids, and mucus transport	Workshop (Chair)
Sigrid Ladores. S18 – Pregnancy & fertility	Symposium (Chair)
Brian Davis. S25 – Genetic repair of CFTR: Advancement of superexon, editing, & related technologies	Symposium (Chair)